SNPs to capture the great majority of SNP variation within each block. 10 Rapid advances in technology and quality control now permit affordable, reliable genotyping of up to 1 million SNPs in a single scan of a person's DNA. 11 Scanning can be used in various study designs, including case-control studies, cohort studies, and clinical trials, as long as it is recognized that the known strengths and weaknesses of these designs are pertinent to the use of scanning. 12, 13 A complication of genomewide association studies is the enormous number of tests of association required (at least one per SNP); thresholds of statistical significance are stringent, making it necessary to work with very large samples. 14 One frequently used approach to managing size is the tiered design, in which a subset of SNPs found to be significant in the genomewide association study (sometimes called the discovery set) is genotyped in a second tier (a replication set), yielding a smaller subset of significantly associated SNPs that are then tested in a third tier (a second replication set), and so on. 15, 16 This process helps to identify false positive associations. Carrying forward a large number of SNPs identified through a genomewide association study into a test of replication also minimizes false negative results 17 while raising the bar for the establishment of true positive results. The pooling of results obtained in genomewide association studies (Fig. 2) under the auspices of large consortia is often required for the detection of variants with small effects on the risk of disease. Such pooled studies, like all genetic association studies, must be examined and controlled for differences in allele frequency between groups that can lead to spurious (false positive) associations. 12 The most reliable evidence of a true genetic association, short of defining the causal variant functionally, is replication of the association, especially if it appears in multiple populations. 18, 19 Surv ey of Findings Nearly 600 genomewide association studies covering 150 distinct diseases and traits have been published, with nearly 800 SNP-trait associations reported as significant (P<5×10 −8 ) (Fig. 3 ) (an interactive version of Fig. 3 is available with the full text of this article at NEJM.org). 4 Such associations are consistent with the common diseasecommon variant hypothesis, which posits that genetic influences on susceptibility to common diseases are attributable to a limited number of variants present in more than 1% to 5% of the population. 20, 21 The common disease-common variant hypothesis is exemplified by susceptibility to age-related macular degeneration. Five major variants are associated with age-related macular degeneration, and each is associated with a risk of disease that is two to three times the risk for a person without one of the variants. 22 Two of these variants, found in the complement factor H (CFH) gene, are common in the populations studied (allele frequencies of 36% and 57% among unaffected persons), and the other three variants have allele frequencies of 5 to 19% in the populations studied. 23 Taken together, these five variants more than double the risk of age-related macular degeneration in the siblings of affected persons, accounting for roughly half the estimated total risk for siblings, and suggest that the complementmediated inflammation pathway is central to pathogenesis. 23, 24 The discovery that inflammation plays a role in age-related macular degeneration and is proving to be a suitable target for therapeutic intervention in animal models 25, 26 demonstrates the power of the genomewide association study to implicate previously unsuspected pathways in the cause and pathogenesis of disease, leading to the development of new therapies.
The genomewide association study has also yielded more than 30 variants related to Crohn's disease. 27 Three of these variants, found in the genes NOD2, IL23R, and LRRK2, are common (all but one have risk-allele frequencies of more than 9% in the populations studied) and are associated with an increase in risk by a factor of 1.5 to 4. However, the remainder confer very small risk elevations (odds ratios, 1.08 to 1.35) and require extremely large studies for detection. A similar pattern of a few variants having large effects but most having small effects has emerged for type 1 diabetes, with more than 40 variants identified to date. 28, 29 Other common conditions have not been as amenable to investigation of genomewide associations. An early example was schizophrenia. Five genomewide association studies failed to find any variants reaching genomewide significance. 4 A sixth study implicated rare structural variants that disrupt neurodevelopmental pathways, 30 raising questions about the role of structural variants in neuropsychiatric disorders. 31 Subsequent, larger studies investigating the risk of schizophrenia have implicated several variants -both structural variants and SNPs -in the region of the major histocompatibility complex (MHC) and at other loci, associations that have been replicated in independent samples. [32] [33] [34] Generally, associations between SNPs and traits tend to be of modest effect size, with a median odds ratio per copy of the risk allele of 1.33. 7 Several variants carry odds ratios above 3.00, including some exceeding 12.00. These are of particular interest, since it seems likely that there would have been evolutionary pressure against their selection unless they provided some survival ben- The genomewide association study is typically based on a case-control design in which single-nucleotide polymorphisms (SNPs) across the human genome are genotyped. Panel A depicts a small locus on chromosome 9, and thus a very small fragment of the genome. In Panel B, the strength of association between each SNP and disease is calculated on the basis of the prevalence of each SNP in cases and controls. In this example, SNPs 1 and 2 on chromosome 9 are associated with disease, with P values of 10 −12 and 10 −8 , respectively. The plot in Panel C shows the P values for all genotyped SNPs that have survived a quality-control screen, with each chromosome shown in a different color. The results implicate a locus on chromosome 9, marked by SNPs 1 and 2, which are adjacent to each other (graph at right), and other neighboring SNPs. Only 12% of SNPs associated with traits are located in, or occur in tight linkage disequilibrium with, protein-coding regions of genes, although SNPs in protein-coding regions are heavily overrepresented on genotyping arrays (Fig. 4) . 7 Approximately 40% of trait-associated SNPs fall in intergenic regions, and another 40% are located in noncoding introns. These two findings have sharpened the focus on the potential roles of intronic, and particularly intergenic, regions in regulating gene expression. 1 Other surprising findings include the association of SNPs with genes originally not thought to have a role in a given disease (Table 1 ). The potential roles of the complement system in agerelated macular degeneration, a disease previously thought to be primarily degenerative in origin, 39 or of autophagy in inflammatory bowel disease, 40 for example, were not widely suspected until these systems were implicated through genomewide asGlossary Annotation catalog: A map denoting the function of specific genomic regions, such as sites to which noncoding RNA or transcription factors bind. Common disease-common variant hypothesis: The hypothesis that genetic influences on susceptibility to common diseases are attributable to a limited number of variants present in more than 1% to 5% of the population. Complex condition: A condition caused by the interaction of multiple genes and environmental factors. Examples of complex conditions, which are also called multifactorial diseases, are cancer and heart disease. Copy-number variation: Variation from one person to the next in the number of copies of a particular gene or DNA sequence. The full extent to which copy-number variation contributes to human disease is not yet known. Fine mapping: An experimental approach to narrowing a genomewide association signal by typing all known SNPs in the haplotype block containing the tag SNP. If successful, this approach results in the identification of a subsegment of the block that has a stronger association than the surrounding areas. Gene deserts: Large intergenic regions. Haplotype: A set of DNA variations, or polymorphisms, that tend to be inherited together. A haplotype can refer to a combination of alleles or to a set of single-nucleotide polymorphisms found on the same chromosome. Heritability: The proportion of interindividual differences (variance) in a trait that is the result of genetic factors; often estimated on the basis of parent-offspring correlations for continuous traits or the ratio of the incidence in first-degree relatives of affected persons to the incidence in first-degree relatives of unaffected persons. Intergenic regions: Segments of DNA that do not contain or overlap genes. Introns: The portions of a gene that are removed (spliced out) before translation to a protein. Introns may contain regulatory information that is critical to appropriate gene expression. Inversion: A chromosomal segment that has been broken off and reinserted in the same place, but with the genetic sequence in reverse order. Linkage disequilibrium: An association between two alleles located near each other on a chromosome, such that they are inherited together more frequently than would be expected by chance. Low-depth coverage: A preliminary strategy in DNA sequencing whereby each base pair is sequenced a minimum of 2 to 4 times rather than the 20 to 30 times that is characteristic of complete (high-depth) sequencing. Minor-allele frequency: The proportion of the less common of two alleles in a population (with two alleles carried by each person at each autosomal locus), ranging from <1% to <50%. Noncoding RNAs: Segments of RNA that are not translated into amino acid sequences but may be involved in the regulation of gene expression. Nonsynonymous single-nucleotide polymorphism: A polymorphism that results in a change in the amino acid sequence of a protein (and may therefore affect the function of the protein). Rare variant: A genetic variant with a minor-allele frequency of less than 1%. Rare variants are typically single-nucleotide substitutions but can also be structural variants. RNA interference: The inhibition of gene expression by noncoding RNA molecules. Single-nucleotide polymorphism (SNP): A single-nucleotide variation in a genetic sequence; a common form of variation in the human genome. Structural variant: A genetic variant involving the insertion, deletion, duplication, translocation, or inversion of segments of DNA up to millions of bases in length. Tag SNP: A readily measured SNP that is in strong linkage disequilibrium with multiple other SNPs, so that it can serve as a proxy for these SNPs on large-scale genotyping platforms. 1000 Genomes Project: An international collaboration formed to produce an extensive public catalog of human genetic variation, including SNPs and structural variants and the haplotypes on which they occur. Transcription factor: A protein that binds to gene regulatory regions in DNA and helps to control gene expression. Translocation: A chromosomal segment that has been broken off and reinserted in a different place in the genome.
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T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 363;2 nejm.org july 8, 2010 170 sociation studies. Signals falling in large so-called gene deserts, such as the 8q24.22 locus (which includes markers associated with prostate cancer) 41 and the 5p13.1 region (which includes markers associated with Crohn's disease), 42 raised concern initially that they were false positive, spurious associations. However, the repeated replication of these associations has established that the regions clearly exert influences -though as yet unknown -on the diseases.
Similarly, genomewide association studies have identified loci that are shared by conditions previously thought to be unrelated ( Table 2 ). The possibility of common etiologic pathways in such disparate conditions or traits as type 2 diabetes and invasive melanoma, Crohn's disease and Parkinson's disease, or prostate cancer and height raises intriguing questions about the pathophysiology of these seemingly unrelated conditions and about the potential for using drugs that are effective in the treatment of one condition for the treatment of the other. 51
Ch a llenges
Trait-associated SNPs may point the way toward functional genetic variants but are unlikely themselves to be the causative variants, at least given our current understanding of genomic function and regulation. A first step in narrowing a genomewide association signal to potentially causative variants is to type all the known SNPs in the haplotype block represented by the tag SNP (a process known as fine mapping) to determine whether one of these SNPs has a stronger association (than that tag SNP) or an established functional effect. Although this approach has shown promise in identifying causal variants, 52 its yield has been limited. 53 Extensive sequencing of an associated region may identify additional, previously unknown, rare variants (frequency, <1%) with a possible biologic role. The use of this approach has suggested that variants of IFIH1 confer susceptibility to type 1 diabetes, 54 a finding that is consistent with this gene's established role in antiviral responses and the known association between type 1 diabetes and viral infections. Given the lack of good representation of SNPs with a prevalence of less than 5% in current genomewide association arrays, a comprehensive catalogue of SNPs with a prevalence of 1 to 5% is being generated by the 1000 Genomes Project 55 for potential inclusion in fine-mapping efforts and expanded genomewide association arrays. In the project's pilot effort, more than 11 million novel SNPs have been identified in what was ini- tially low-depth coverage of 172 persons. 56 Geneexpression data may also implicate a particular gene as underlying an association signal, as suggested by expression data implicating the gene PTGER4 in a genomewide association study of Crohn's disease. 42 Annotation catalogues (maps of functions of variants), such as those related to transcription-factor binding (promoting gene expression) or to RNA interference (silencing genes), are currently in development and should facilitate the identification of functional variants underlying genomewide association signals. 57 The small proportion of heritability and risk of disease typically explained by genomewide association findings presents a challenge: how to identify the variants that confer the outstanding risk -the risk that has not been accounted for. 58 Larger genomewide association studies that identify more variants are likely to identify variants with even smaller effect sizes. The importance of structural variation, including copy-number variants, inversions, and translocations, is an active area of investigation; several structural variants underlie genomewide association signals for autism, schizophrenia, Crohn's disease, and obesity. 31, 59 Also needed are studies of population samples with diverse geographic ancestries, particularly recent African ancestry. These older populations, which have undergone more mutations and a greater number of recombination events, have greater degrees of genetic variation and shorter stretches of linkage disequilibrium, allowing for better localization of genomewide association signals. 6, 8 R isk A ssessment
The potential for variants identified in genomewide association studies to predict the risk of complex diseases has been anticipated since the publication of the first reports, but this application is problematic. 22, 60 The question of how best to assess the usefulness of genetic variants in disease prediction is the subject of lively debate, and optimal metrics for assessing the clinical effect have yet to be identified. Most would agree, however, that appropriate considerations extend beyond odds ratios or population attributable risks to more complex measures such as the area under the receiver-operating-characteristic curve (AUC) and risk-reclassification statistics. 61, 62 For the prediction of complex diseases, genotypes at multiple SNPs are often combined into scores calculated according to the number of risk alleles carried, which is the approach that Kathiresan and colleagues used in predicting the risk of cardiovascular disease on the basis of nine SNPs associated with cholesterol levels. 63 This score was strongly associated with the risk of cardiovascular disease even after adjustment for standard risk factors, including family history, but the AUC was unchanged after inclusion of the genotype score. 63 Among the subjects initially considered to be at intermediate risk for cardiovascular disease (9% of the total cohort), 26% were reclassified in the low-risk or high-risk category, and reclassification statistics showed significant improvement in risk classification. The reclassifications had implications for clinical care as recommended in standard clinical guidelines. On closer analysis, however, the reclassifications were based on only minor increments in the risk score, which shifted subjects with borderline scores from one category to the next 60 (Fig. 5) . Indeed, collective odds ratios of 200 or more may be necessary if The frequency of a specific functional classification among trait-associated SNPs (TAS) and their linkage disequilibrium partners is shown in blue. The frequency of functional classifications among SNPs randomly drawn from genotyping arrays is shown in pink (r 2 ≥0.8). The abbreviation miRTS denotes microRNA target site. Nonsynonymous SNPs (Nonsyn) are associated with one or more traits nearly three times as often as randomly selected SNPs, and 5′ promoter SNPs nearly twice as often. Although intronic and intergenic SNPs are not overrepresented in associations as compared with randomly selected SNPs, they account for the great majority -more than 80% -of associated SNPs. TFBS denotes transcription-factor-binding site and UTR untranslated region. there is to be meaningful reclassification of subjects on the basis of risk. 64 Similar attempts to use multiple SNPs to predict the risk of prostate cancer have also been of limited value, with minimal improvements in the AUC, as compared with the use of standard clinical risk factors, and identification of only a small proportion of subjects (<2%) at the highest levels of risk. 61, 65 Evidence that genotype scores may be of particular value in predicting risk among persons with a family history of a particular condition is intriguing and should be explored in studies of conditions other than heart disease and prostate cancer. 61, 66 What is becoming clear from these early attempts at genetically based risk assessment is that currently known variants explain too little about the risk of disease occurrence to be of clinically useful predictive value. One can anticipate that as sample sizes increase and more risk variants are identified, the predictive value of cumulative genotypic scores will increase. 22, 67, 68 It has also been argued that the use of dense genotyping information, from tens of thousands of SNPs with only nominal associations with disease, may improve the accuracy of phenotypic prediction. 34 Care is needed in evaluating genetic predictive models, since they are often specific to the population in which they were developed, and their value can vary with genotypic frequencies, effect sizes, and disease incidence. 68 Possible clinical uses of predictive scores -for example, in deciding which patients should be screened more intensively for breast cancer with the use of mammography 69 or for statin-induced myopathy with the use of muscle enzyme assays 70 -will require rigorous, preferably prospective, evaluation before being accepted into clinical practice.
Genomewide scans permit screening for many conditions at once. If binomial probabilities were applied to 40 independent diseases, for example, roughly 90% of the population would be placed in the top 5% of those at genetic risk for at least one of the diseases, 33% would be in the top 1%, and 4% would be in the top 0.1%. 71 Expanding such screening to 120 diseases would nearly triple the proportion in the top 0.001% at risk and identify 1.2% at the top 0.01%, levels that could justify population-based screening if appropriate interventions were available. The ability to assess risk for 120 conditions at the same time also raises the concern that predictive models will yield conflicting recommendations; if implemented, they could reduce a person's risk for development of one condition and exacerbate the risk for development of another.
Such considerations are timely and important, since several commercial ventures are marketing genomewide association-based screening directly to consumers. 72 This testing can often be obtained without a physician's intercession and has been promoted for medical, genealogic, and even recreational purposes. The information provided to the customer is often founded on scant evidence and based on average risks that are difficult to apply to an individual person. 73 Few factors associated with differences in risk across a population will separate affected and unaffected groups widely enough to be useful for individual prediction. 64 Adequate communication of disease risk is a topic that has challenged generations of physicians and patients, and the perception of risk is more often influenced by emotion than by science. Genome-based risk information may not improve communication of risk, but its uniquely individual nature may be personally motivating and could be explored with respect to the promotion of salutary behaviors.
Patients inquiring about genomewide association testing should be advised that at present the results of such testing have no value in predicting risk and are not clinically directive. Clinicians would do well to use the discussion as an oppor- Despite the limitations of using data obtained from genomewide association studies to assess the individual patient's level of risk for a particular condition, genomewide scans may be useful in initiating counseling about nongenetic risk factors or perhaps in screening for a very high risk of many conditions at once. Continued efforts to identify genetic variants that influence the response to drugs may yield new associations that could be used to tailor drug selection and dosing to the profile of the individual patient, particularly if it becomes possible to query these data through a user-friendly interface when a medication is ordered. The substantial challenges of incorporating such research into clinical care must be pursued if the potential of genomic medicine is to be realized.
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